Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20265585 | 0.81 | PLAU (0.49) | NPSR1PLAUFLT3NTRK1ADORA3 | |
| SCHEMBL24967123 | 0.78 | IRAK4 (0.56) | NPSR1PLAUFLT3NTRK1ADORA3 | |
| Dimethylamine SCHEMBL7859896 | 0.77 | NPSR1 (0.46) | NPSR1FLT3ADORA3DYRK1AMIF | |
| SCHEMBL16051889 | 0.77 | TGFBR1 (0.49) | NPSR1PLAUFLT3NTRK1ADORA3 | |
| SCHEMBL10146037 | 0.77 | GPR84 (0.49) | NPSR1PLAUFLT3ADORA3DYRK1A | |
| Methylamine SCHEMBL9796918 | 0.76 | ADRA1B (0.44) | NPSR1PLAUFLT3NTRK1ADORA3 | |
| SCHEMBL2289203 | 0.76 | GAA (0.50) | NPSR1PLAUFLT3NTRK1IRAK4 | |
| SCHEMBL28269101 | 0.75 | SMN1; SMN2 (0.59) | ADORA3ALDH1A1NPC1HPGDKDM4E | |
| SCHEMBL21863679 | 0.74 | ALDH1A1 (0.49) | FLT3ALDH1A1NPC1HPGDKDM4E | |
| SCHEMBL7156465 | 0.74 | PLAU (0.51) | NPSR1PLAUNTRK1IRAK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342025-B2 | Substituted C-imidazo[1,2-a]pyridin-3-yl-methylamines | GRUENENTHAL GMBH (DE) | 2008-03-11 | — | — | US | claimed |
| EP-1549647-B1 | SUBSTITUTED C-IMIDAZO¬1,2-A|PYRIDIN-3-YL-METHYLAMINES | GRUENENTHAL GMBH (DE) | 2006-04-12 | — | — | EP | claimed |
| EP-1549650-B1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | GRUENENTHAL GMBH (DE) | 2006-03-22 | — | — | EP | claimed |
| US-20050239822-A1 | Substituted C-imiadazol[1,2-a] pyridin-3-yl-methylamines | GRUENENTHAL GMBH (DE) | 2005-10-27 | — | — | US | claimed |
| EP-1549650-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2005-07-06 | — | — | EP | claimed |
| EP-1549647-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2005-07-06 | — | — | EP | claimed |
| WO-2004035578-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2004-04-29 | — | — | WO | claimed |
| WO-2004033453-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2004-04-22 | — | — | WO | claimed |
| WO-2024124002-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2021122745-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2021-06-24 | — | — | WO | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-2129375-B1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-04-25 | — | — | EP | disclosed |
| US-7342025-B2 | Substituted C-imidazo[1,2-a]pyridin-3-yl-methylamines | GRUENENTHAL GMBH (DE) | 2008-03-11 | — | — | US | disclosed |
| US-7342025-B2 | Substituted C-imidazo[1,2-a]pyridin-3-yl-methylamines | GRUENENTHAL GMBH (DE) | 2008-03-11 | — | — | US | disclosed |
| EP-1549650-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1549647-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004035578-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035578-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004033453-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004033453-A1 | SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES | Grünenthal GmbH (DE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239822-A1 | Substituted C-imiadazol[1,2-a] pyridin-3-yl-methylamines | NOS2, NOS1, NOS3 | NPSR1 2788/4885PLAU 2176/4885FLT3 798/4885 |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | NPSR1 1983/4885PLAU 1167/4885FLT3 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.